📊 XOMAP Key Takeaways
Is XOMA Royalty Corp (XOMAP) a Good Investment?
Exceptional revenue growth of 403.9% YoY and industry-leading net margins of 60.8% are undermined by severe cash flow deterioration—negative free cash flow of -96.1M and interest coverage below 1x indicate the company cannot cover debt servicing from operations, raising questions about earnings quality and financial sustainability despite reported profitability.
XOMA Royalty Corp Key Strengths (XOMAP)
- Exceptional YoY revenue growth of 403.9% with net income up 71.3%
- Outstanding profitability metrics: 60.8% net margin, 37.8% ROE, and 21.8% operating margin
- Strong balance sheet liquidity with 3.37x current ratio and $82.9M in cash equivalents
XOMAP Stock Risks: XOMA Royalty Corp Investment Risks
- Severely negative free cash flow of -96.1M despite profitability; company burns cash operationally
- Interest coverage of 0.9x indicates operating income cannot cover interest expenses; financial distress signal
- Disconnect between reported $31.7M net income and only $2.9M operating cash flow; significant earnings quality concerns
- Capital expenditure of $99M on $52.1M revenue is unsustainable and dependent on external financing or cash depletion
Key Metrics to Watch
- Operating cash flow trend and cash conversion quality relative to reported earnings
- Interest coverage improvement and debt service sustainability
- Free cash flow path to positive and capex as percentage of revenue normalization
XOMA Royalty Corp (XOMAP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.37x current ratio provides a solid financial cushion.
XOMAP Profit Margin, ROE & Profitability Analysis
XOMAP vs Healthcare Sector: How XOMA Royalty Corp Compares
How XOMA Royalty Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is XOMA Royalty Corp Stock Overvalued? XOMAP Valuation Analysis 2026
Based on fundamental analysis, XOMA Royalty Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
XOMA Royalty Corp Balance Sheet: XOMAP Debt, Cash & Liquidity
XOMAP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: XOMA Royalty Corp's revenue has declined by 72% over the 5-year period, indicating business contraction. The most recent EPS of $-1.65 indicates the company is currently unprofitable.
XOMAP Revenue Growth, EPS Growth & YoY Performance
XOMAP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $4.0M | $2.4M | $0.06 |
| Q3 2025 | $25.0K | $2.4M | $0.70 |
| Q2 2025 | $5.0M | $2.4M | $0.27 |
| Q1 2025 | $1.0M | $2.4M | $0.06 |
| Q3 2024 | $25.0K | -$5.4M | $-0.60 |
| Q2 2024 | $1.1M | -$5.4M | $0.27 |
| Q1 2024 | $1.0M | -$8.6M | $-0.86 |
| Q3 2023 | $25.0K | -$2.3M | $-0.48 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
XOMA Royalty Corp Dividends, Buybacks & Capital Allocation
XOMAP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for XOMA Royalty Corp (CIK: 0000791908)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 26, 2026 | 4 | xslF345X06/marketforms-73268.xml | View → |
| May 26, 2026 | 4 | xslF345X06/marketforms-73269.xml | View → |
| May 26, 2026 | 4 | xslF345X06/marketforms-73267.xml | View → |
| May 26, 2026 | 4 | xslF345X06/marketforms-73265.xml | View → |
| May 26, 2026 | 4 | xslF345X06/marketforms-73264.xml | View → |
❓ Frequently Asked Questions about XOMAP
What is the AI rating for XOMAP?
XOMA Royalty Corp (XOMAP) has an AI grade of B with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XOMAP's key strengths?
Claude: Exceptional YoY revenue growth of 403.9% with net income up 71.3%. Outstanding profitability metrics: 60.8% net margin, 37.8% ROE, and 21.8% operating margin.
What are the risks of investing in XOMAP?
Claude: Severely negative free cash flow of -96.1M despite profitability; company burns cash operationally. Interest coverage of 0.9x indicates operating income cannot cover interest expenses; financial distress signal.
What is XOMAP's revenue and growth?
XOMA Royalty Corp reported revenue of $52.1M.
Does XOMAP pay dividends?
XOMA Royalty Corp pays dividends, with $5.5M distributed to shareholders in the trailing twelve months.
Where can I find XOMAP SEC filings?
Official SEC filings for XOMA Royalty Corp (CIK: 0000791908) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XOMAP's EPS?
XOMA Royalty Corp has a diluted EPS of $1.46.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is XOMAP's fundamental grade?
Based on our AI fundamental analysis in June 2026, XOMA Royalty Corp has a B grade with 68% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is XOMAP stock overvalued or undervalued?
Valuation metrics for XOMAP: ROE of 37.8% (sector avg: 15%), net margin of 60.8% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
What is XOMAP's AI grade for 2026?
Our dual AI analysis gives XOMA Royalty Corp a combined B grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is XOMAP's free cash flow?
XOMA Royalty Corp's operating cash flow is $2.9M, with capital expenditures of $99.0M. FCF margin is -184.3%.
How does XOMAP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 60.8% (avg: 12%), ROE 37.8% (avg: 15%), current ratio 3.37 (avg: 2).
Why is XOMAP's return on equity (ROE) so high?
XOMA Royalty Corp has a return on equity of 37.8%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 60.8% net margin.